Download PDF
Planta Med 2022; 88(14): 1348-1359
DOI: 10.1055/a-1708-1994
Natural Product Chemistry and Analytical Studies
Original Papers

Characterization of Different Forms of Kava (Piper methysticum) Products by UPLC-MS/MS

Jessica Mamallapalli‡
1   Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA
,
Siva Rama Raju Kanumuri‡
2   Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, USA
3   Translational Drug Development Core, Clinical and Translational Science Institute, University of Florida, Gainesville, FL, USA
,
Pedro Corral
1   Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA
,
Edward Johnston
4   The Association for Hawaiian Awa (kava), Pepeʼekeo, HI, USA
,
Chunlin Zhuang
5   School of Pharmacy, Second Military Medical University, Shanghai, China
,
Christopher R. McCurdy
1   Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA
2   Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, USA
3   Translational Drug Development Core, Clinical and Translational Science Institute, University of Florida, Gainesville, FL, USA
,
Carol A. Mathews
6   Department of Psychiatry, College of Medicine, University of Florida, Gainesville, FL, USA
,
Abhisheak Sharma 
2   Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, USA
3   Translational Drug Development Core, Clinical and Translational Science Institute, University of Florida, Gainesville, FL, USA
,
Chengguo Xing
1   Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA
› Author AffiliationsSupported by: National Institute of General Medical Sciences T32GM136583
Supported by: National Center for Complementary and Integrative Health R61AT009988
Supported by: Center for Scientific Review UL1TR001427
› Further Information
    Permissions and Reprints

Abstract

There are several forms of kava (Piper methysticum) products available for human consumption, and many factors are known to influence their chemical compositions and therefore their pharmacological properties. Because of the increased popularity of kava intake, a rigorous characterization of their content diversity is prerequisite, particularly due to its known potential to cause hepatotoxicity. To understand the composition diversity of kavalactones and flavokavains in commercial kava products, we developed a UPLC-MS/MS-based analytical method for the quantification of six kavalactones (kavain, dihydrokavain, methysticin, dihydromethysticin, yangonin and desmethoxyyangonin) and two flavokavains (flavokavains A and B) and analyzed their contents in 28 different kava products in the form of capsules, tinctures, traditional aqueous suspensions and dried powders. Our results demonstrated a great variation in terms of the total and relative abundance of the analyzed kavalactones and flavokavains among the analyzed kava preparations. More importantly, the kavalactone abundance in the product label could differ up to 90% from our experimental measurements. Therefore, more rigorous and comprehensive quality control of kava products is required with respect to the content of individual kavalactones and flavokavains. Accurate content information is essential to understand the pharmacological properties and safety of different kava products.

Key words

Kava - kavalactones - flavokavains - UPLC-MS/MS - Piper methysticum - Piperaceae

Supporting Information

    Information about the different forms of analyzed kava products, extraction scheme, accuracy and precision of the assay method, stability and recovery efficiency of analytes from kava products is available as Supporting Information.

  • Supporting Information


Publication History

Received: 27 July 2021

Accepted after revision: 28 November 2021

Accepted Manuscript online:
28 November 2021

Article published online:
22 August 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Volgin A, Yang L, Amstislavskaya T, Demin K, Wang D, Yan D, Wang J, Wang M, Alpyshov E, Hu G, Serikuly N, Shevyrin V, Wappler-Guzzetta E, de Abreu M, Kalueff A. DARK classics in chemical neuroscience: Kava. ACS Chemical Neuroscience 2020; DOI: 10.1021/acschemneuro.9b00587.
    CrossrefPubMedGoogle Scholar
  • 2 WHO. Kava: A review of the safety of tradtional and recreational beverage consumption. Food and Agriculture Organization of the United Nation 2016; 1: 1-35
    PubMedGoogle Scholar
  • 3 Wheatley D. Kava and valerian in the treatment of stress-induced insomnia. Phytother Res 2001; 15: 549-551
    CrossrefPubMedGoogle Scholar
  • 4 Ooi SL, Henderson P, Pak SC. Kava for generalized anxiety disorder: a review of current evidence. Journal of alternative and complementary medicine 2018; DOI: 10.1089/acm.2018.0001.
    CrossrefPubMedGoogle Scholar
  • 5 Münte TF, Heinze HJ, Matzke M, Steitz J. Effects of oxazepam and an extract of kava roots (Piper methysticum) on event-related potentials in a word recognition task. Neuropsychobiology 1993; 27: 46-53
    CrossrefPubMedGoogle Scholar
  • 6 Pollastri MP, Whitty A, Merrill JC, Tang X, Ashton TD, Amar S. Identification and characterization of kava-derived compounds mediating TNF-alpha suppression. Chem Biol Drug Des 2009; 74: 121-128 DOI: 10.1111/j.1747-0285.2009.00838.x.
    CrossrefPubMedGoogle Scholar
  • 7 Johnson TE, Kassie F, OʼSullivan MG, Negia M, Hanson TE, Upadhyaya P, Ruvolo PP, Hecht SS, Xing C. Chemopreventive effect of kava on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone plus benzo[a]pyrene-induced lung tumorigenesis in A/J mice. Cancer Prev Res (Phila) 2008; 1: 430-438 DOI: 10.1158/1940-6207.CAPR-08-0027.
    CrossrefPubMedGoogle Scholar
  • 8 Leitzman P, Narayanapillai SC, Balbo S, Zhou B, Upadhyaya P, Shaik AA, OʼSullivan MG, Hecht SS, Lu J, Xing C. Kava blocks 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis in association with reducing O6-methylguanine DNA adduct in A/J mice. Cancer Prev Res 2014; 7: 86-96 DOI: 10.1158/1940-6207.CAPR-13-0301.
    CrossrefPubMedGoogle Scholar
  • 9 Johnson TE, Hermanson D, Wang L, Kassie F, Upadhyaya P, OʼSullivan MG, Hecht SS, Lu J, Xing C. Lung tumorigenesis suppressing effects of a commercial kava extract and its selected compounds in A/J mice. Am J Chin Med 2011; 39: 727-742 DOI: 10.1142/S0192415X11009202.
    CrossrefPubMedGoogle Scholar
  • 10 Narayanapillai SC, Balbo S, Leitzman P, Grill AE, Upadhyaya P, Shaik AA, Zhou B, OʼSullivan MG, Peterson LA, Lu J, Hecht SS, Xing C. Dihydromethysticin from kava blocks tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis and differentially reduces DNA damage in A/J mice. Carcinogenesis 2014; 35: 2365-2372 DOI: 10.1093/carcin/bgu149.
    CrossrefPubMedGoogle Scholar
  • 11 Tang SN, Zhang J, Jiang P, Datta P, Leitzman P, OʼSullivan MG, Jiang C, Xing C, Lü J. Gene expression signatures associated with suppression of TRAMP prostate carcinogenesis by a kavalactone-rich kava fraction. Mol Carcinog 2016; 55: 2291-2303 DOI: 10.1002/mc.22469.
    CrossrefPubMedGoogle Scholar
  • 12 Triolet J, Shaik AA, Gallaher DD, OʼSullivan MG, Xing C. Reduction in colon cancer risk by consumption of kava or kava fractions in carcinogen-treated rats. Nutr Cancer 2012; 64: 838-846 DOI: 10.1080/01635581.2012.689917.
    CrossrefPubMedGoogle Scholar
  • 13 Einbond LS, Negrin A, Kulakowski DM, Wu HA, Antonetti V, Jalees F, Law W, Roller M, Redenti S, Kennelly EJ, Balick MJ. Traditional preparations of kava (Piper methysticum) inhibit the growth of human colon cancer cells in vitro . Phytomedicine 2017; 24: 1-13 DOI: 10.1016/j.phymed.2016.11.002.
    CrossrefPubMedGoogle Scholar
  • 14 Li X, Liu Z, Xu X, Blair CA, Sun Z, Xie J, Lilly MB, Zi X. Kava components down-regulate expression of AR and AR splice variants and reduce growth in patient-derived prostate cancer xenografts in mice. PLoS One 2012; 7: e31213-e31213 DOI: 10.1371/journal.pone.0031213.
    CrossrefPubMedGoogle Scholar
  • 15 Bian T, Corral P, Wang Y, Botello J, Kingston R, Daniels T, Salloum RG, Johnston E, Huo Z, Lu J, Liu AC, Xing C. Kava as a clinical nutrient: promises and challenges. Nutrients 2020; 12: 3044 DOI: 10.3390/nu12103044.
    CrossrefPubMedGoogle Scholar
  • 16 Teschke R, Schwarzenboeck A, Hennermann KH. Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases. Eur J Gastroenterol Hepatol 2008; 20: 1182-1193 DOI: 10.1097/MEG.0b013e3283036768.
    CrossrefPubMedGoogle Scholar
  • 17 Côté CS, Kor C, Cohen J, Auclair K. Composition and biological activity of traditional and commercial kava extracts. Biochem Biophys Res Commun 2004; 322: 147-152
    CrossrefPubMedGoogle Scholar
  • 18 Teschke R, Qiu SX, Lebot V. Herbal hepatotoxicity by kava: Update on pipermethystine, flavokavain B, and mould hepatotoxins as primarily assumed culprits. Dig Liver Dis 2011; 43: 676-681 DOI: 10.1016/j.dld.2011.01.018.
    CrossrefPubMedGoogle Scholar
  • 19 Coulter D, Tamayo C, Sotheeswaran S, Ulbricht C. World Health Organization. Assessment of the risk of hepatotoxicity with kava products. Geneva: World Health Organization; 2007. Accessed January 14, 2022 at: https://apps.who.int/iris/handle/10665/43630
    Google Scholar
  • 20 Olsen LR, Grillo MP, Skonberg C. Constituents in kava extracts potentially involved in hepatotoxicity: a review. Chem Res Toxicol 2011; 24: 992-1002 DOI: 10.1021/Tx100412m.
    CrossrefPubMedGoogle Scholar
  • 21 Clouatre DL. Kava kava: Examining new reports of toxicity. Toxicol Lett 2004; 150: 85-96
    CrossrefPubMedGoogle Scholar
  • 22 Stickel F, Baumüller HM, Seitz K, Vasilakis D, Seitz G, Seitz HK, Schuppan D. Hepatitis induced by Kava (Piper methysticum rhizoma). J Hepatol 2003; 39: 62-67
    CrossrefPubMedGoogle Scholar
  • 23 Martin AC, Johnston E, Xing C, Hegeman AD. Measuring the chemical and cytotoxic variability of commercially available kava (Piper methysticum G. Forster). PLoS One 2014; 9: e111572
    CrossrefPubMedGoogle Scholar
  • 24 Mohanty M. Fiji Kava: production, trade, role and challenges. JPacS 2017; 37: 5-30
    CrossrefPubMedGoogle Scholar
  • 25 Nelson S. Farm and forestry production and marketing profile for kava (Piper methysticum). In: Elevitch CR. ed. Specialty Crops for Pacific Island. Holualoa, HI: Agroforestry Publisher, Permanent Agriculture Resources; 2021
    Google Scholar
  • 26 Johnston E, Rogers H. eds. Hawaiian ‘Awa: views of an ethnobotanical treasure. Hilo, HI: Association for Hawaiian ‘Awa; 2006
    Google Scholar
  • 27 Bian T, Corral P, Wang Y, Botello J, Kingston R, Daniels T, Salloum RG, Johnston E, Huo Z, Lu J, Liu AC, Xing C. Kava as a clinical nutrient: Promises and challenges. Nutrients 2020; 12: 3044
    CrossrefPubMedGoogle Scholar
  • 28 Lebot V, Michalet S, Legendre L. Kavalactones and flavokavins profiles contribute to quality assessment of kava (Piper methysticum G. Forst.), the traditional beverage of the pacific. Beverages 2019; 5: 34
    CrossrefPubMedGoogle Scholar
  • 29 Lebot V, Do TK, Legendre L. Detection of flavokavins (A, B, C) in cultivars of kava (Piper methysticum) using high performance thin layer chromatography (HPTLC). Food Chem 2014; 151: 554-560 DOI: 10.1016/j.foodchem.2013.11.120.
    CrossrefPubMedGoogle Scholar
  • 30 Martin AC, Johnston E, Xing C, Hegeman AD. Measuring the chemical and cytotoxic variability of commercially available kava (Piper methysticum G. Forster). PLoS One 2014; 9: e111572 DOI: 10.1371/journal.pone.0111572.
    CrossrefPubMedGoogle Scholar
  • 31 Li Y, Mei H, Wu Q, Zhang S, Fang JL, Shi L, Guo L. Methysticin and 7,8-dihydromethysticin are two major kavalactones in kava extract to induce CYP1A1. Toxicol Sci 2011; 124: 388-399 DOI: 10.1093/toxsci/kfr235.
    CrossrefPubMedGoogle Scholar
  • 32 Zhou P, Gross S, Liu JH, Yu BY, Feng LL, Nolta J, Sharma V, Piwnica-Worms D, Qiu SX. Flavokawain B, the hepatotoxic constituent from kava root, induces GSH-sensitive oxidative stress through modulation of IKK/NF-kappa B and MAPK signaling pathways. FASEB J 2010; 24: 4722-4732 DOI: 10.1096/Fj.10-163311.
    CrossrefPubMedGoogle Scholar
  • 33 Narayanapillai SC, Leitzman P, OʼSullivan MG, Xing C. Flavokawains a and b in kava, not dihydromethysticin, potentiate acetaminophen-induced hepatotoxicity in C57BL/6 mice. Chem Res Toxicol 2014; 27: 1871-1876 DOI: 10.1021/tx5003194.
    CrossrefPubMedGoogle Scholar
  • 34 [Anonymous] ICH harmonised tripartite guideline. Q2(R1): Validation of Analytical Procedures: Text and Methodology. Accessed April 20, 2021 at: https://database.ich.org/sites/default/files/Q2_R1__Guideline.pdf
    PubMedGoogle Scholar
  • 35 Lasme P, Davrieux F, Montet D, Lebot V. Quantification of kavalactones and determination of kava (Piper methysticum) chemotypes using near-infrared reflectance spectroscopy for quality control in vanuatu. J Agric Food Chem 2008; 56: 4976-4981 DOI: 10.1021/jf800439g.
    CrossrefPubMedGoogle Scholar
  • 36 Pluskal T, Torrens-Spence MP, Fallon TR, De Abreu A, Shi CH, Weng JK. The biosynthetic origin of psychoactive kavalactones in kava. Nat Plants 2019; 5: 867-878 DOI: 10.1038/s41477-019-0474-0.
    CrossrefPubMedGoogle Scholar
  • 37 Shaik AA, Hermanson DL, Xing C. Identification of methysticin as a potent and non-toxic NF-kappaB inhibitor from kava, potentially responsible for kavaʼs chemopreventive activity. Bioorg Med Chem Lett 2009; 19: 5732-5736 DOI: 10.1016/j.bmcl.2009.08.003.
    CrossrefPubMedGoogle Scholar
  • 38 Srinivasan B, Johnson TE, Xing C. Chalcone-based inhibitors against hypoxia-inducible factor 1–structure activity relationship studies. Bioorg Med Chem Lett 2011; 21: 555-557 DOI: 10.1016/j.bmcl.2010.10.063.
    CrossrefPubMedGoogle Scholar